<- Go Home
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Market Cap
$2.0B
Volume
1.5M
Cash and Equivalents
$40.7M
EBITDA
$153.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$233.5M
Profit Margin
78.27%
52 Week High
$16.88
52 Week Low
$7.29
Dividend
N/A
Price / Book Value
3.52
Price / Earnings
7.03
Price / Tangible Book Value
3.54
Enterprise Value
$1.7B
Enterprise Value / EBITDA
10.71
Operating Income
$134.3M
Return on Equity
64.98%
Return on Assets
13.66
Cash and Short Term Investments
$378.5M
Debt
$68.6M
Equity
$567.6M
Revenue
$298.3M
Unlevered FCF
$127.3M
Sector
Biotechnology
Category
N/A